HEALGEN SCIENTIFIC LLC C/O JOE XIA BUSINESS DIRECTOR 504 EAST DIAMOND AVE. SUITE I GAITHERSBURG MD 20877

Re: K150096 Trade/Device Name: Healgen MDMA (Ecstasy) Test (Strip, Cassette, Cup, Dip Card), Healgen Phencyclidine Test (Strip, Cassette, Cup, Dip Card) Regulation Number: 21 CFR 862.3610 Regulation Name: Methamphetamine test system Regulatory Class: II Product Code: LAF, LCM Dated: January 12, 2015 Received: January 20, 2015

Dear Mr. Xia:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

Page 2—Mr. Xia

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address   
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, “Misbranding by reference to premarket notification” (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH’s Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

# Katherine Serrano -A

Courtney H. Lias, Ph.D.For: Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

510(k) Number (if known) k150096

Device Name Healgen MDMA (Ecstasy) Test (Strip, Cassette, Cup, Dip Card) Healgen Phencyclidine Test (Strip, Cassette, Cup, Dip Card)

Indications for Use (Describe)   
Healgen MDMA (Ecstasy) Test is an immunochromatographic assay for the qualitative determination of   
Methylenedioxymethamphetamine in human urine at a Cut-Off concentration of $5 0 0 ~ \mathrm { { n g / m L } }$ .The test is available in a Strip format, a Cassette format, a Dip Card format and a Cup format.

T  euiu hul uh u For in vitro diagnostic use only. It is intended for prescription and for over-the-counter use.

Heecliditraphielitatienatihc human urine at a Cut-Off concentration of $2 5 ~ \mathrm { n g / m L }$ . The test is available in a Strip format, a Cassette format, a Dip Card format and a Cup format.

Th ovi eaeulm peaivlus uC huu u u For in vitro diagnostic use only. It is intended for prescription and for over-the-counter use.

# CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\*

T buren timolectioationate veragour nclu eviw istructionssear existin dat sourcs athanmaintai edt eede n cple a review the collection iformation Send comments garding ths burden estimate or any oheraspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

# 510(k) SUMMARY

1. Date:

February 26, 2015

2. Submitter:

HEALGEN SCIENTIFIC LLC   
5213 Maple St   
Bellaire, TX 77401

3. Contact person:

Jianqiu Fang   
HEALGEN SCIENTIFIC LLC   
5213 Maple St   
Bellaire, TX 77401   
Telephone: 713-733-8088   
Fax: 713-733-8088   
Email: bryan@healgen.com

4. Device Name: Healgen MDMA (Ecstasy) Test (Strip, Cassette, Cup, Dip Card) Healgen Phencyclidine Test (Strip, Cassette, Cup, Dip Card)

Classification:   

<table><tr><td rowspan=1 colspan=1>Product Code</td><td rowspan=1 colspan=1>CFR #</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>LCM</td><td rowspan=1 colspan=1>This device has not been classified.</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>LAF</td><td rowspan=1 colspan=1>21 CFR, 862.3610 Methamphetamine Test System</td><td rowspan=1 colspan=1>Toxicology</td></tr></table>

5. Predicate Devices:

K052115   
First Check Multi Drug Cup 12

6. Intended Use / Indications for Use Healgen MDMA (Ecstasy) Test is an immunochromatographic assay for the qualitative determination of Methylenedioxymethamphetamine in human urine at a Cut-Off concentration of $5 0 0 ~ \mathrm { { n g / m L } }$ . The test is available in a Strip format, a Cassette format, a Dip Card format and a Cup format.

The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. GC/MS is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.

For in vitro diagnostic use only. It is intended for prescription and for over-the-counter use.

Healgen Phencyclidine Test is an immunochromatographic assay for the qualitative determination of Phencyclidine in human urine at a Cut-Off concentration of $2 5 ~ \mathrm { n g / m L }$ . The test is available in a Strip format, a Cassette format, a Dip Card format and a Cup format.

The test provides only preliminary test results. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. GC/MS is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary result is positive.

For in vitro diagnostic use only. It is intended for prescription and for over-the-counter use.

# 7. Device Description

Healgen MDMA (Ecstasy) Test and Healgen Phencyclidine Test are immunochromatographic assays for Methylenedioxymethamphetamine and Phencyclidine. Each assay test is a lateral flow system for the qualitative detection of Methylenedioxymethamphetamine and Phencyclidine (target analyte) in human urine. The products are in vitro diagnostic devices, which come in the form of: Strips, Cassettes, DipCards, or Cups. Each product contains a Test Device (in one of the four formats), and a package insert. Each test device is sealed with a desiccant in an aluminum pouch.

8. Substantial Equivalence Information A summary comparison of features of the Healgen MDMA (Ecstasy) Test and Healgen Phencyclidine Test and the predicate device is provided in Table 1 & Table 2.

Table 1: Features Comparison of Healgen MDMA (Ecstasy) Test and the Predicate Device   
Table 2: Features Comparison of Healgen Phencyclidine Test and the Predicate Device   

<table><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate -K052115</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">For the qualitative determination of drugsof abuse in human urine.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Drug Analyte</td><td colspan="1" rowspan="1">Methylenedioxymethamphetamine</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Methodology</td><td colspan="1" rowspan="1">Competitive binding, lateral flowimmunochromatographic assays based onthe principle of antigen antibodyimmunochemistry.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Specimen Type</td><td colspan="1" rowspan="1">Human Urine</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Cut-Off Values</td><td colspan="1" rowspan="1">500 ng/mL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">IntendedPopulation</td><td colspan="1" rowspan="1">For over-the-counter and prescriptionuses.</td><td colspan="1" rowspan="1">Forover-the-counteruse.</td></tr><tr><td colspan="1" rowspan="1">Configurations</td><td colspan="1" rowspan="1">Strip, Cassette, Cup, Dip Card</td><td colspan="1" rowspan="1">Cup</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">Device</td><td colspan="1" rowspan="1">Predicate - K052115</td></tr><tr><td colspan="1" rowspan="1">Intended Use</td><td colspan="1" rowspan="1">For the qualitative determination ofdrugs of abuse in human urine.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Drug Analyte</td><td colspan="1" rowspan="1">Phencyclidine</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Methodology</td><td colspan="1" rowspan="1">Competitive binding, lateral flowimmunochromatographic assays basedon the principle of antigen antibodyimmunochemistry.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Specimen Type</td><td colspan="1" rowspan="1">Human Urine</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Cut-Off Values</td><td colspan="1" rowspan="1">25 ng/mL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">IntendedPopulation</td><td colspan="1" rowspan="1">For over-the-counter and prescriptionuses.</td><td colspan="1" rowspan="1">For over-the-counteruse.</td></tr><tr><td colspan="1" rowspan="1">Configurations</td><td colspan="1" rowspan="1">Strip, Cassette, Cup, Dip Card</td><td colspan="1" rowspan="1">Cup</td></tr></table>

# 9. Test Principle

Healgen MDMA (Ecstasy) Test and Healgen Phencyclidine Test are rapid tests for the qualitative detection of Methylenedioxymethamphetamine and Phencyclidine in urine samples. Each assay test is a lateral flow chromatographic immunoassay. During testing, a urine specimen migrates upward by capillary action. If target drugs are present in the urine specimen below its cut-off concentration, it will not saturate the binding sites of its specific antibody (monoclonal mouse antibody) coated on the particles. The antibody-coated particles will then be captured by immobilized drug-conjugate and a visible colored line will show up in the test line region. The colored line will not form in the test line region if the target drug level exceeds its cut-offconcentration because it will saturate all the binding sites of the antibody coated on the particles. A band should form in the control region of the devices regardless of the presence of drug or metabolite in the sample to indicate that the test has been performed properly.

# 10. Performance Characteristics

1. Analytical Performance

a. Precision

Precision studies were carried out for samples with concentrations of - $\cdot 1 0 0 \%$ cut-off, $- 7 5 \%$ cut-off, - $. 5 0 \%$ cut-off, $- 2 5 \%$ cut-off, at the cut-off, $+ 2 5 \%$ cut-off, $+ 5 0 \%$ cut-off, $+ 7 5 \%$ cut-off and $+ 1 0 0 \%$ cut-off. These samples were prepared by spiking drug in negative samples. Each drug concentration was confirmed by GC/MS. All sample aliquots were blind labeled and randomized by the person who prepared samples and did not take part in the sample testing. For each concentration, tests were performed two runs per day for 25 days by three different operators for each format of devices. Different set of operators tested each format. The results obtained are summarized in the following tables:

# MDMA (Ecstasy)

Strip Format   

<table><tr><td rowspan=1 colspan=1>ResultDrug</td><td rowspan=1 colspan=1>-100%Cut-off</td><td rowspan=1 colspan=1>-75%Cut-off</td><td rowspan=1 colspan=1>-50%Cut-off</td><td rowspan=1 colspan=1>-25%Cut-off</td><td rowspan=1 colspan=1>Cut-off</td><td rowspan=1 colspan=1>+25%Cut-off</td><td rowspan=1 colspan=1>+50%Cut-off</td><td rowspan=1 colspan=1>+75%Cut-off</td><td rowspan=1 colspan=1>+100%Cut-off</td></tr><tr><td rowspan=1 colspan=1>Lot:MDMA1201001</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>22-/28+</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>Lot:MDMA1201002</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>22-/28+</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>Lot:MDMA1201003</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>22-/28+</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr></table>

Cassette Format   

<table><tr><td rowspan=1 colspan=1>ResultDrug</td><td rowspan=1 colspan=1>-100%Cut-off</td><td rowspan=1 colspan=1>-75%Cut-off</td><td rowspan=1 colspan=1>-50%Cut-off</td><td rowspan=1 colspan=1>-25%Cut-off</td><td rowspan=1 colspan=1>Cut-off</td><td rowspan=1 colspan=1>+25%Cut-off</td><td rowspan=1 colspan=1>+50%Cut-off</td><td rowspan=1 colspan=1>+75%Cut-off</td><td rowspan=1 colspan=1>+100%Cut-off</td></tr><tr><td rowspan=1 colspan=1>Lot:MDMA1201004</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>22-/28+</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>Lot:MDMA1201005</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>22-/28+</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>Lot:MDMA1201006</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>22-/28+</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr></table>

Dip Card Format   

<table><tr><td>Result</td><td>-100%</td><td>-75%</td><td>-50%</td><td>-25%</td><td>Cut-off</td><td>+25%</td><td>+50%</td><td>+75%</td><td>+100%</td></tr><tr><td>Drug</td><td>Cut-off</td><td>Cut-off</td><td>Cut-off</td><td>Cut-off</td><td></td><td>Cut-off</td><td>Cut-off</td><td>Cut-off</td><td>Cut-off</td></tr><tr><td>Lot:MDMA1201007</td><td>50-/0+</td><td>50-/0+</td><td>50-/0+</td><td>50-/0+</td><td>24-/26+</td><td>50+/0-</td><td>50+/0-</td><td>50+/0-</td><td>50+/0-</td></tr><tr><td>Lot:MDMA1201008</td><td>50-/0+</td><td>50-/0+</td><td>50-/0+</td><td>50-/0+</td><td>24-/26+</td><td>50+/0-</td><td>50+/0-</td><td>50+/0-</td><td>50+/0-</td></tr><tr><td>Lot:MDMA1201009</td><td>50-/0+</td><td>50-/0+</td><td>50-/0+</td><td>50-/0+</td><td>24-/26+</td><td>50+/0-</td><td>50+/0-</td><td>50+/0-</td><td>50+/0-</td></tr></table>

CUP Format   

<table><tr><td rowspan=1 colspan=1>ResultDrug</td><td rowspan=1 colspan=1>-100%Cut-off</td><td rowspan=1 colspan=1>-75%Cut-off</td><td rowspan=1 colspan=1>-50%Cut-off</td><td rowspan=1 colspan=1>-25%Cut-off</td><td rowspan=1 colspan=1>Cut-off</td><td rowspan=1 colspan=1>+25%Cut-off</td><td rowspan=1 colspan=1>+50%Cut-off</td><td rowspan=1 colspan=1>+75%Cut-off</td><td rowspan=1 colspan=1>+100%Cut-off</td></tr><tr><td rowspan=1 colspan=1>Lot:MDMA1201010</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>30-/20+</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>Lot:MDMA1201011</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>30-/20+</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>Lot:MDMA1201012</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>30-/20+</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr></table>

Phencyclidine Strip Format b. Linearity Not applicable.

<table><tr><td rowspan=1 colspan=1>ResultDrug</td><td rowspan=1 colspan=1>-100%Cut-off</td><td rowspan=1 colspan=1>-75%Cut-off</td><td rowspan=1 colspan=1>-50%Cut-off</td><td rowspan=1 colspan=1>-25%Cut-off</td><td rowspan=1 colspan=1>Cut-off</td><td rowspan=1 colspan=1>+25%Cut-off</td><td rowspan=1 colspan=1>+50%Cut-off</td><td rowspan=1 colspan=1>+75%Cut-off</td><td rowspan=1 colspan=1>+100%Cut-off</td></tr><tr><td rowspan=1 colspan=1>Lot:PCP1111001</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>20-/30+</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>Lot:PCP1111002</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>20-/30+</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>Lot:PCP1111003</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>20-/30+</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr></table>

Cassette Format   

<table><tr><td>Result</td><td>-100%</td><td>-75%</td><td>-50%</td><td>-25%</td><td>Cut-off</td><td>+25%</td><td>+50%</td><td>+75%</td><td>+100%</td></tr><tr><td>Drug</td><td>Cut-off</td><td>Cut-off</td><td>Cut-off</td><td>Cut-off</td><td></td><td>Cut-off</td><td>Cut-off</td><td>Cut-off</td><td>Cut-off</td></tr><tr><td>Lot:PCP1111004</td><td>50-/0+</td><td>50-/0+</td><td>50-/0+</td><td>50-/0+</td><td>18-/32+</td><td>50+/0-</td><td>50+/0-</td><td>50+/0-</td><td>50+/0-</td></tr><tr><td>Lot:PCP1111005</td><td>50-/0+</td><td>50-/0+</td><td>50-/0+</td><td>50-/0+</td><td>18-/32+</td><td>50+/0-</td><td>50+/0-</td><td>50+/0-</td><td>50+/0-</td></tr><tr><td>Lot:PCP1111006</td><td>50-/0+</td><td>50-/0+</td><td>50-/0+</td><td>50-/0+</td><td>18-/32+</td><td>50+/0-</td><td>50+/0-</td><td>50+/0-</td><td>50+/0-</td></tr></table>

Dip Card Format   

<table><tr><td rowspan=1 colspan=1>ResultDrug</td><td rowspan=1 colspan=1>-100%Cut-off</td><td rowspan=1 colspan=1>-75%Cut-off</td><td rowspan=1 colspan=1>-50%Cut-off</td><td rowspan=1 colspan=1>-25%Cut-off</td><td rowspan=1 colspan=1>Cut-off</td><td rowspan=1 colspan=1>+25%Cut-off</td><td rowspan=1 colspan=1>+50%Cut-off</td><td rowspan=1 colspan=1>+75%Cut-off</td><td rowspan=1 colspan=1>+100%Cut-off</td></tr><tr><td rowspan=1 colspan=1>Lot:PCP1111007</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>22-/28+</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>Lot:PCP1111008</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>22-/28+</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>Lot:PCP1111009</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>22-/28+</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr></table>

CUP Format   

<table><tr><td rowspan=1 colspan=1>ResultDrug</td><td rowspan=1 colspan=1>-100%Cut-off</td><td rowspan=1 colspan=1>-75%Cut-off</td><td rowspan=1 colspan=1>-50%Cut-off</td><td rowspan=1 colspan=1>-25%Cut-off</td><td rowspan=1 colspan=1>Cut-off</td><td rowspan=1 colspan=1>+25%Cut-off</td><td rowspan=1 colspan=1>+50%Cut-off</td><td rowspan=1 colspan=1>+75%Cut-off</td><td rowspan=1 colspan=1>+100%Cut-off</td></tr><tr><td rowspan=1 colspan=1>Lot:PCP1111010</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>16-/34+</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>Lot:PCP1111011</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>16-/34+</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr><tr><td rowspan=1 colspan=1>Lot:PCP1111012</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>50-/0+</td><td rowspan=1 colspan=1>16-/34+</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td><td rowspan=1 colspan=1>50+/0-</td></tr></table>

c. Stability The devices are stable at $4 { - } 3 0 ^ { \circ } \mathrm { C }$ for 24 months based on the accelerated stability study at $4 5 \mathrm { ^ \circ C }$ and real time stability determination at both $4 ^ { \circ } \mathrm { C }$ and $3 0 \%$ .

Control materials are not provided with the device. The labeling provides information on how to obtain control materials.

d. Cut-off

A total of 150 samples equally distributed at concentrations of - $- 5 0 \%$ cut-off; $- 2 5 \%$ cut-off; cut-off; $+ 2 5 \%$ cut-off; $+ 5 0 \%$ cut-off were tested using three different lots of each device by three different operators. Results were all positive at and above $+ 2 5 \%$ cut-off and all negative at and below $- 2 5 \%$ cut-off for both Methylenedioxymethamphetamine and Phencyclidine. The following cut-off values for the test devices have been verified.

<table><tr><td>Test</td><td>Calibrator</td><td>Cut-off (ng/mL)</td></tr><tr><td colspan="1" rowspan="1">MDMA (Ecstasy) Test</td><td colspan="1" rowspan="1">Methylenedioxymethamphetamine</td><td colspan="1" rowspan="1">500</td></tr><tr><td colspan="1" rowspan="1">Phencyclidine Test</td><td colspan="1" rowspan="1">Phencyclidine</td><td colspan="1" rowspan="1">25</td></tr></table>

e. Interference

Potential interfering substances found in human urine of physiological or pathological conditions were added to drug-free urine and target drugs urine with concentration at $2 5 \%$ below and $2 5 \%$ above cut-off levels. These urine samples were tested using three batches of each device for all formats.

Compounds that showed no interference at a concentration of $1 0 0 \mu \mathrm { g / m L }$ are summarized in the following tables. There were no differences observed for different formats.

MDMA (Ecstasy)   

<table><tr><td colspan="1" rowspan="1">Acetophenetidin</td><td colspan="1" rowspan="1">Ethyl Morphine</td><td colspan="1" rowspan="1">Phenelzine</td></tr><tr><td colspan="1" rowspan="1">N-Acetylprocainamide</td><td colspan="1" rowspan="1">Ethyl-p-aminobenzoate</td><td colspan="1" rowspan="1">Phenobarbital</td></tr><tr><td colspan="1" rowspan="1">Acetylsalicylic Acid(Aspirin)</td><td colspan="1" rowspan="1">Fenoprofen</td><td colspan="1" rowspan="1">Phentermine</td></tr><tr><td colspan="1" rowspan="1">Aminopyrine</td><td colspan="1" rowspan="1">Furosemide</td><td colspan="1" rowspan="1">Phenylephrine-L</td></tr><tr><td colspan="1" rowspan="1">Amitriptyline</td><td colspan="1" rowspan="1">Gentisic acid</td><td colspan="1" rowspan="1">Phenylethylamine</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin</td><td colspan="1" rowspan="1">Hemoglobin</td><td colspan="1" rowspan="1">Phenylpropanolamine</td></tr><tr><td colspan="1" rowspan="1">Amobarbital</td><td colspan="1" rowspan="1">Hydralazine</td><td colspan="1" rowspan="1">Prednisolone Acetate</td></tr><tr><td colspan="1" rowspan="1">D-Amphetamine</td><td colspan="1" rowspan="1">(+/-)-4-HydroxyamphetamineHCL</td><td colspan="1" rowspan="1">Prednisone</td></tr><tr><td colspan="1" rowspan="1">L-Amphetamine</td><td colspan="1" rowspan="1">Hydrochlorothiazide</td><td colspan="1" rowspan="1">Procaine(Novocaine)</td></tr><tr><td colspan="1" rowspan="1">Amphetamine Sulfate</td><td colspan="1" rowspan="1">Hydrocodone</td><td colspan="1" rowspan="1">Promazine</td></tr><tr><td colspan="1" rowspan="1">Ampicinine(Ampicillin)</td><td colspan="1" rowspan="1">Hydrocortisone</td><td colspan="1" rowspan="1">Promethazine</td></tr><tr><td colspan="1" rowspan="1">Apomorphine</td><td colspan="1" rowspan="1">a -Hydroxyhippuric acid</td><td colspan="1" rowspan="1">Propoxyphene,d-</td></tr><tr><td colspan="1" rowspan="1">L-Ascorbic Acid</td><td colspan="1" rowspan="1">p-Hydroxymethamphetamine</td><td colspan="1" rowspan="1">Propranolol</td></tr><tr><td colspan="1" rowspan="1">Aspartame</td><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">Pseudoephedrine HCL</td></tr><tr><td colspan="1" rowspan="1">Atropine</td><td colspan="1" rowspan="1">Imipramine</td><td colspan="1" rowspan="1">Quinidine</td></tr><tr><td colspan="1" rowspan="1">Benzilic acid</td><td colspan="1" rowspan="1">Isoxsuprine</td><td colspan="1" rowspan="1">Quinine</td></tr><tr><td colspan="1" rowspan="1">Benzphetamine</td><td colspan="1" rowspan="1">Isoproterenol-(+/-)</td><td colspan="1" rowspan="1">Ranitidine(Zantac)</td></tr><tr><td colspan="1" rowspan="1">Bezoic Acid</td><td colspan="1" rowspan="1">Ketamine</td><td colspan="1" rowspan="1">Salicylic Acid</td></tr><tr><td colspan="1" rowspan="1">Bilirubin</td><td colspan="1" rowspan="1">Levorphanol</td><td colspan="1" rowspan="1">Secobarbital</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">Loperamide</td><td colspan="1" rowspan="1">Serotonin</td></tr><tr><td colspan="1" rowspan="1">Chloramphenicol</td><td colspan="1" rowspan="1">Maprotiline</td><td colspan="1" rowspan="1">Sulfamethazine</td></tr><tr><td colspan="1" rowspan="1">Chlordiazepoxide HCL</td><td colspan="1" rowspan="1">Meprobamate</td><td colspan="1" rowspan="1">Sulindac</td></tr><tr><td colspan="1" rowspan="1">Chloroquine</td><td colspan="1" rowspan="1">Methadone</td><td colspan="1" rowspan="1">Temazepam</td></tr><tr><td colspan="1" rowspan="1">Chlorothiazide</td><td colspan="1" rowspan="1">Methoxyphenamine</td><td colspan="1" rowspan="1">11-Nor-Δ-Tetrahydrocannabinol</td></tr><tr><td colspan="1" rowspan="1">Chlorpheniramine</td><td colspan="1" rowspan="1">Methylphenidate</td><td colspan="1" rowspan="1">Tetracycline</td></tr><tr><td colspan="1" rowspan="1">Chlorpromazine</td><td colspan="1" rowspan="1">Nalbuphine</td><td colspan="1" rowspan="1">Tetrahydrozoline</td></tr><tr><td colspan="1" rowspan="1">Cholesterol</td><td colspan="1" rowspan="1">Nalidixic acid</td><td colspan="1" rowspan="1">Thebaine</td></tr><tr><td colspan="1" rowspan="1">Clomipramine</td><td colspan="1" rowspan="1">Naloxone hydrochloride</td><td colspan="1" rowspan="1">Thiamine</td></tr><tr><td colspan="1" rowspan="1">Clonidine hydrochloride</td><td colspan="1" rowspan="1">Naltrexone hydrochloride</td><td colspan="1" rowspan="1">L-Thyroxine</td></tr><tr><td colspan="1" rowspan="1">Codeine</td><td colspan="1" rowspan="1">Naproxen</td><td colspan="1" rowspan="1">ThioridazineHydrochloride</td></tr><tr><td colspan="1" rowspan="1">Cortisone</td><td colspan="1" rowspan="1">Niacinamide</td><td colspan="1" rowspan="1">Triamterene</td></tr><tr><td colspan="1" rowspan="1">Cotinine(-)</td><td colspan="1" rowspan="1">Nifedipine</td><td colspan="1" rowspan="1">TriflupromazineHydrochloride</td></tr><tr><td colspan="1" rowspan="1">Creatinine</td><td colspan="1" rowspan="1">Norethindrone</td><td colspan="1" rowspan="1">Trimethoprim</td></tr><tr><td colspan="1" rowspan="1">Deoxyepinephrine</td><td colspan="1" rowspan="1">Norpropoxyphene</td><td colspan="1" rowspan="1">Trimipramine</td></tr><tr><td colspan="1" rowspan="1">Dextromethorphan</td><td colspan="1" rowspan="1">Noscapine</td><td colspan="1" rowspan="1">Tryptamine</td></tr><tr><td colspan="1" rowspan="1">Diazepam</td><td colspan="1" rowspan="1">Oxazepam</td><td colspan="1" rowspan="1">DL-Tryptophan</td></tr><tr><td colspan="1" rowspan="1">Diflunisal</td><td colspan="1" rowspan="1">Oxycodone</td><td colspan="1" rowspan="1">Tyramine</td></tr><tr><td colspan="1" rowspan="1">Digoxin</td><td colspan="1" rowspan="1">Oxymetazoline</td><td colspan="1" rowspan="1">D/L-Tyrosine</td></tr><tr><td colspan="1" rowspan="1">Doxylamine</td><td colspan="1" rowspan="1">Papaverine</td><td colspan="1" rowspan="1">Uric Acid</td></tr><tr><td colspan="1" rowspan="1">Ecgonine methylester</td><td colspan="1" rowspan="1">Penicillin</td><td colspan="1" rowspan="1">Verapamil</td></tr><tr><td colspan="1" rowspan="1">R(-)-Epinephrine</td><td colspan="1" rowspan="1">Pentobarbital</td><td colspan="1" rowspan="1">Zomepirac</td></tr><tr><td colspan="1" rowspan="1">Erythromycin</td><td colspan="1" rowspan="1">Perphenazine</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Estrone-3-sulfate</td><td colspan="1" rowspan="1">Phencyclidine</td><td colspan="1" rowspan="1"></td></tr></table>

# Phencyclidine

<table><tr><td colspan="1" rowspan="1">Acetophenetidin</td><td colspan="1" rowspan="1">Ethyl-p-aminobenzoate</td><td colspan="1" rowspan="1">Phenelzine</td></tr><tr><td colspan="1" rowspan="1">N-Acetylprocainamide</td><td colspan="1" rowspan="1">Fenoprofen</td><td colspan="1" rowspan="1">Phenobarbital</td></tr><tr><td colspan="1" rowspan="1">Acetylsalicylic Acid(Aspirin)</td><td colspan="1" rowspan="1">Furosemide</td><td colspan="1" rowspan="1">Phentermine</td></tr><tr><td colspan="1" rowspan="1">Aminopyrine</td><td colspan="1" rowspan="1">Gentisic acid</td><td colspan="1" rowspan="1">Phenylephrine-L</td></tr><tr><td colspan="1" rowspan="1">Amitriptyline</td><td colspan="1" rowspan="1">Hemoglobin</td><td colspan="1" rowspan="1">Phenylethylamine</td></tr><tr><td colspan="1" rowspan="1">Amoxicillin</td><td colspan="1" rowspan="1">Hydralazine</td><td colspan="1" rowspan="1">Phenylpropanolamine</td></tr><tr><td colspan="1" rowspan="1">Amobarbital</td><td colspan="1" rowspan="1">(+/-)-4-HydroxyamphetamineHCL</td><td colspan="1" rowspan="1">Prednisolone Acetate</td></tr><tr><td colspan="1" rowspan="1">D-Amphetamine</td><td colspan="1" rowspan="1">Hydrochlorothiazide</td><td colspan="1" rowspan="1">Prednisone</td></tr><tr><td colspan="1" rowspan="1">L-Amphetamine</td><td colspan="1" rowspan="1">Hydrocodone</td><td colspan="1" rowspan="1">Procaine(Novocaine)</td></tr><tr><td colspan="1" rowspan="1">Amphetamine Sulfate</td><td colspan="1" rowspan="1">Hydrocortisone</td><td colspan="1" rowspan="1">Promazine</td></tr><tr><td colspan="1" rowspan="1">Ampicinine(Ampicillin)</td><td colspan="1" rowspan="1">a -Hydroxyhippuric acid</td><td colspan="1" rowspan="1">Promethazine</td></tr><tr><td colspan="1" rowspan="1">Apomorphine</td><td colspan="1" rowspan="1">p-Hydroxymethamphetamine</td><td colspan="1" rowspan="1">Propoxyphene,d-</td></tr><tr><td colspan="1" rowspan="1">L-Ascorbic Acid</td><td colspan="1" rowspan="1">Ibuprofen</td><td colspan="1" rowspan="1">Propranolol</td></tr><tr><td colspan="1" rowspan="1">Aspartame</td><td colspan="1" rowspan="1">Imipramine</td><td colspan="1" rowspan="1">Pseudoephedrine HCL</td></tr><tr><td colspan="1" rowspan="1">Atropine</td><td colspan="1" rowspan="1">Isoxsuprine</td><td colspan="1" rowspan="1">Quinidine</td></tr><tr><td colspan="1" rowspan="1">Benzilic acid</td><td colspan="1" rowspan="1">Isoproterenol-(+/-)</td><td colspan="1" rowspan="1">Quinine</td></tr><tr><td colspan="1" rowspan="1">Benzphetamine</td><td colspan="1" rowspan="1">Ketamine</td><td colspan="1" rowspan="1">Ranitidine(Zantac)</td></tr><tr><td colspan="1" rowspan="1">Bezoic Acid</td><td colspan="1" rowspan="1">Labetalol</td><td colspan="1" rowspan="1">Salicylic Acid</td></tr><tr><td colspan="1" rowspan="1">Bilirubin</td><td colspan="1" rowspan="1">Levorphanol</td><td colspan="1" rowspan="1">Secobarbital</td></tr><tr><td colspan="1" rowspan="1">Caffeine</td><td colspan="1" rowspan="1">Loperamide</td><td colspan="1" rowspan="1">Serotonin</td></tr><tr><td colspan="1" rowspan="1">Chloramphenicol</td><td colspan="1" rowspan="1">Maprotiline</td><td colspan="1" rowspan="1">Sulfamethazine</td></tr><tr><td colspan="1" rowspan="1">ChlordiazepoxideHCL</td><td colspan="1" rowspan="1">Meprobamate</td><td colspan="1" rowspan="1">Sulindac</td></tr><tr><td colspan="1" rowspan="1">Chloroquine</td><td colspan="1" rowspan="1">Methadone</td><td colspan="1" rowspan="1">Temazepam</td></tr><tr><td colspan="1" rowspan="1">Chlorothiazide</td><td colspan="1" rowspan="1">Methoxyphenamine</td><td colspan="1" rowspan="1">11-Nor-Δ-Tetrahydrocannabinol</td></tr><tr><td colspan="1" rowspan="1">Chlorpheniramine</td><td colspan="1" rowspan="1">(+/-)-Methylenedioxyamphetamine(MDA)</td><td colspan="1" rowspan="1">Tetracycline</td></tr><tr><td colspan="1" rowspan="1">Chlorpromazine</td><td colspan="1" rowspan="1">Methylphenidate</td><td colspan="1" rowspan="1">Tetrahydrozoline</td></tr><tr><td colspan="1" rowspan="1">Cholesterol</td><td colspan="1" rowspan="1">Nalbuphine</td><td colspan="1" rowspan="1">Thebaine</td></tr><tr><td colspan="1" rowspan="1">Clomipramine</td><td colspan="1" rowspan="1">Nalidixic acid</td><td colspan="1" rowspan="1">Thiamine</td></tr><tr><td colspan="1" rowspan="1">Clonidine hydrochloride</td><td colspan="1" rowspan="1">Naloxone hydrochloride</td><td colspan="1" rowspan="1">L-Thyroxine</td></tr><tr><td colspan="1" rowspan="1">Codeine</td><td colspan="1" rowspan="1">Naltrexone hydrochloride</td><td colspan="1" rowspan="1">ThioridazineHydrochloride</td></tr><tr><td colspan="1" rowspan="1">Cortisone</td><td colspan="1" rowspan="1">Naproxen</td><td colspan="1" rowspan="1">Triamterene</td></tr><tr><td colspan="1" rowspan="1">Cotinine(-)</td><td colspan="1" rowspan="1">Niacinamide</td><td colspan="1" rowspan="1">TriflupromazineHydrochloride</td></tr><tr><td colspan="1" rowspan="1">Creatinine</td><td colspan="1" rowspan="1">Nifedipine</td><td colspan="1" rowspan="1">Trimethoprim</td></tr><tr><td colspan="1" rowspan="1">Deoxyepinephrine</td><td colspan="1" rowspan="1">Norethindrone</td><td colspan="1" rowspan="1">Trimipramine</td></tr><tr><td colspan="1" rowspan="1">Dextromethorphan</td><td colspan="1" rowspan="1">Norpropoxyphene</td><td colspan="1" rowspan="1">Tryptamine</td></tr><tr><td colspan="1" rowspan="1">Diazepam</td><td colspan="1" rowspan="1">Noscapine</td><td colspan="1" rowspan="1">DL-Tryptophan</td></tr><tr><td colspan="1" rowspan="1">Diflunisal</td><td colspan="1" rowspan="1">Oxazepam</td><td colspan="1" rowspan="1">Tyramine</td></tr><tr><td colspan="1" rowspan="1">Digoxin</td><td colspan="1" rowspan="1">Oxycodone</td><td colspan="1" rowspan="1">D/L-Tyrosine</td></tr><tr><td colspan="1" rowspan="1">Doxylamine</td><td colspan="1" rowspan="1">Oxymetazoline</td><td colspan="1" rowspan="1">Uric Acid</td></tr><tr><td colspan="1" rowspan="1">Ecgonine methylester</td><td colspan="1" rowspan="1">Papaverine</td><td colspan="1" rowspan="1">Verapamil</td></tr><tr><td colspan="1" rowspan="1">R(-)-Epinephrine</td><td colspan="1" rowspan="1">Penicillin</td><td colspan="1" rowspan="1">Zomepirac</td></tr><tr><td colspan="1" rowspan="1">Erythromycin</td><td colspan="1" rowspan="1">Pentobarbital</td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">Estrone-3-sulfate</td><td colspan="1" rowspan="1">Perphenazine</td><td colspan="1" rowspan="1">Y</td></tr></table>

# f. Specificity

To test the specificity, drug metabolites and other components that are likely to interfere in urine samples were tested using three batches of each device for all formats. The obtained lowest detectable concentration was used to calculate the cross-reactivity. There were no differences observed for different formats.

<table><tr><td>MDMA</td><td>Result</td><td>%</td></tr><tr><td></td><td></td><td></td></tr><tr><td colspan="1" rowspan="1">Methylenedioxymethamphetamine(Cut-off=500 ng/mL)</td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Cross-Reactivity</td></tr><tr><td colspan="1" rowspan="1">Methylenedioxymethamphetamine</td><td colspan="1" rowspan="1">Positive at 500 ng/mL</td><td colspan="1" rowspan="1">100%</td></tr><tr><td colspan="1" rowspan="1">3,4-Methylenedioxyamphetamine HCl(MDA)</td><td colspan="1" rowspan="1">Positive at 3000 ng/mL</td><td colspan="1" rowspan="1">17%</td></tr><tr><td colspan="1" rowspan="1">3,4-Methylenedioxyethylamphetamine(MDEA)</td><td colspan="1" rowspan="1">Positive at 300 ng/mL</td><td colspan="1" rowspan="1">167%</td></tr><tr><td colspan="1" rowspan="1">d-methamphetamine</td><td colspan="1" rowspan="1">Positive at 2500 ng/mL</td><td colspan="1" rowspan="1">20%</td></tr><tr><td colspan="1" rowspan="1">d-amphetamine</td><td colspan="1" rowspan="1">&gt;100,000</td><td colspan="1" rowspan="1">Not detected</td></tr><tr><td colspan="1" rowspan="1">1-amphetamine</td><td colspan="1" rowspan="1">&gt;100,000</td><td colspan="1" rowspan="1">Not detected</td></tr><tr><td colspan="1" rowspan="1">1-methamphetamine</td><td colspan="1" rowspan="1">&gt;100,000</td><td colspan="1" rowspan="1">Not detected</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Phencyclidine(Cut-off=25 ng/mL)</td><td rowspan=1 colspan=1>Result</td><td rowspan=1 colspan=1>% Cross-Reactivity</td></tr><tr><td rowspan=1 colspan=1>Phencyclidine</td><td rowspan=1 colspan=1>Positive at 25 ng/mL</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>4-Hydroxy Phencyclidine</td><td rowspan=1 colspan=1>Positive at 90 ng/mL</td><td rowspan=1 colspan=1>28%</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr></table>

# g. Effect of Urine Specific Gravity and Urine pH

To investigate the effect of urine specific gravity and urine $\mathrm { p H } _ { \mathrm { \Omega } }$ , urine samples with of 1.000 to 1.035 specific gravity or urine samples with $\mathsf { p H } 4$ to 9 were spiked with target drugs at $2 5 \%$ below and $2 5 \%$ above cut-off levels. These samples were tested using three batches of each device for all formats. Results were all positive for samples at and above $+ 2 5 \%$ cut-off and all negative for samples at and below $- 2 5 \%$ Cut-Off. There were no differences observed for different formats.

# 2. Comparison Studies

The method comparison studies for the MDMA (Ecstasy) Test, and the Phencyclidine Test were performed in-house with three different laboratory assistants for each format of the device. Operators ran 80 (40 negative and 40 positive) unaltered clinical samples. The samples were blind labeled and compared to GC/MS results. The results are presented in the tables below:

MDMA (Ecstasy)   

<table><tr><td rowspan=1 colspan=1>Stripformat</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>LowNegativeby GC/MS(less than-50%</td><td rowspan=1 colspan=1>Near CutoffNegative byGC/MS(Between-50% andcut-off)</td><td rowspan=1 colspan=1>NearCutoffPositive byGC/MS(Betweenthe cut-offand +50%)</td><td rowspan=1 colspan=1>HighPositive byGC/MS(greaterthan +50%)</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>24</td></tr></table>

Discordant Results of MDMA (Ecstasy) Strip   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer B</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer C</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Viewer</td><td rowspan=1 colspan=1>Sample Number</td><td rowspan=1 colspan=1>GC/MS Result</td><td rowspan=1 colspan=1>Strip FormatViewer Results</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>1008</td><td rowspan=1 colspan=1>509</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>1033</td><td rowspan=1 colspan=1>505</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>1076</td><td rowspan=1 colspan=1>507</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>1008</td><td rowspan=1 colspan=1>509</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>1033</td><td rowspan=1 colspan=1>505</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>1076</td><td rowspan=1 colspan=1>507</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>1037</td><td rowspan=1 colspan=1>511</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>1008</td><td rowspan=1 colspan=1>509</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>1033</td><td rowspan=1 colspan=1>505</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>1076</td><td rowspan=1 colspan=1>507</td><td rowspan=1 colspan=1>Negative</td></tr></table>

Discordant Results of MDMA (Ecstasy) Cassette   

<table><tr><td rowspan=1 colspan=1>Cassetteformat</td><td rowspan=1 colspan=1>b</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>LowNegativeby GC/MS(less than-50%)</td><td rowspan=1 colspan=1>NearCutoffNegativeby GC/MS(Between-50% andcut-off)</td><td rowspan=1 colspan=1>Near CutoffPositive byGC/MS(Betweenthe cut-offand +50%)</td><td rowspan=1 colspan=1>HighPositive byGC/MS(greaterthan+50%)</td></tr><tr><td rowspan=2 colspan=1>Viewer A</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer B</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer C</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td></tr></table>

<table><tr><td colspan="1" rowspan="1">Viewer</td><td colspan="1" rowspan="1">Sample Number</td><td colspan="1" rowspan="1">GC/MS Result</td><td colspan="1" rowspan="1">Cassette FormatViewer Results</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">1008</td><td colspan="1" rowspan="1">509</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">1033</td><td colspan="1" rowspan="1">505</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">1076</td><td colspan="1" rowspan="1">507</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">1033</td><td colspan="1" rowspan="1">505</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">1037</td><td colspan="1" rowspan="1">511</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer</td><td colspan="1" rowspan="1">Sample Number</td><td colspan="1" rowspan="1">GC/MS Result</td><td colspan="1" rowspan="1">CassetteFormatViewerResults</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">1076</td><td colspan="1" rowspan="1">507</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">1033</td><td colspan="1" rowspan="1">505</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">1076</td><td colspan="1" rowspan="1">507</td><td colspan="1" rowspan="1">Negative</td></tr></table>

<table><tr><td rowspan=4 colspan=1>Cupformat</td><td rowspan=4 colspan=1>b</td><td rowspan=4 colspan=1>Negative</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>Near Cutoff</td><td rowspan=1 colspan=1>Near Cutoff</td><td rowspan=4 colspan=1>HighPositive byGC/MS(greaterthan+50%)</td></tr><tr><td rowspan=2 colspan=1>Negativeby GC/MS</td><td rowspan=1 colspan=1>Negative by</td><td rowspan=1 colspan=1>Positive by</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>GC/MS</td><td rowspan=1 colspan=1>GC/MS</td></tr><tr><td rowspan=1 colspan=1>(less than-50%)</td><td rowspan=1 colspan=1>(Between-50% andcut-off)</td><td rowspan=1 colspan=1>(Betweenthe cut-offand +50%)</td></tr><tr><td rowspan=2 colspan=1>Viewer A</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer B</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer C</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr></table>

Discordant Results of MDMA (Ecstasy) Cup   

<table><tr><td rowspan=1 colspan=1>Viewer</td><td rowspan=1 colspan=1>Sample Number</td><td rowspan=1 colspan=1>GC/MS Result</td><td rowspan=1 colspan=1>Cup FormatViewer Results</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>1008</td><td rowspan=1 colspan=1>509</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>1033</td><td rowspan=1 colspan=1>505</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>1076</td><td rowspan=1 colspan=1>507</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>1008</td><td rowspan=1 colspan=1>509</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>1033</td><td rowspan=1 colspan=1>505</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>1076</td><td rowspan=1 colspan=1>507</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>1037</td><td rowspan=1 colspan=1>511</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>1008</td><td rowspan=1 colspan=1>509</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>1033</td><td rowspan=1 colspan=1>505</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>1076</td><td rowspan=1 colspan=1>507</td><td rowspan=1 colspan=1>Negative</td></tr></table>

<table><tr><td>Dip Card format</td><td></td><td>Negative</td><td>Low Negative by GC/MS (less than -50%)</td><td>Near Cutoff Negative by GC/MS (Between -50% and</td><td>Near Cutoff Positive by GC/MS (Between the cut-off</td><td>High Positive by GC/MS (greater than</td></tr><tr><td>Viewer A</td><td>Positive</td><td>0</td><td>0</td><td>cut-off) 0</td><td>and +50%) 14</td><td>+50%) 24</td></tr></table>

Discordant Results of MDMA (Ecstasy) Dip Card   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer B</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer C</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Viewer</td><td rowspan=1 colspan=1>Sample Number</td><td rowspan=1 colspan=1>GC/MS Result</td><td rowspan=1 colspan=1>Dip Card FormatViewer Results</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>1033</td><td rowspan=1 colspan=1>505</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>1076</td><td rowspan=1 colspan=1>507</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>1033</td><td rowspan=1 colspan=1>505</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>1008</td><td rowspan=1 colspan=1>509</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>1033</td><td rowspan=1 colspan=1>505</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>1076</td><td rowspan=1 colspan=1>507</td><td rowspan=1 colspan=1>Negative</td></tr></table>

# Phencyclidine

<table><tr><td rowspan=6 colspan=1>Stripformat</td><td rowspan=6 colspan=1>b</td><td rowspan=6 colspan=1>Negative</td><td rowspan=1 colspan=1>Low</td><td rowspan=1 colspan=1>Near Cutoff</td><td rowspan=2 colspan=1>Near CutoffPositive by</td><td rowspan=2 colspan=1>HighPositive by</td></tr><tr><td rowspan=3 colspan=1>Negativeby GC/MS</td><td rowspan=4 colspan=1>Negative byGC/MS(Between-50% and</td></tr><tr><td rowspan=4 colspan=1>by GC/MS(less than-50%)</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>GC/MS</td><td rowspan=1 colspan=1>GC/MS</td></tr><tr><td rowspan=1 colspan=1>(Betweenthe cut-off</td><td rowspan=2 colspan=1>(greaterthan+50%)</td></tr><tr><td rowspan=1 colspan=1>cut-off)</td><td rowspan=1 colspan=1>and +50%)</td></tr><tr><td rowspan=2 colspan=1>Viewer A</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer B</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer C</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr></table>

Discordant Results of Phencyclidine Strip   

<table><tr><td colspan="1" rowspan="1">Viewer</td><td colspan="1" rowspan="1">Sample Number</td><td colspan="1" rowspan="1">GC/MS Result</td><td colspan="1" rowspan="1">Strip FormatViewer Results</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">774</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">721</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">779</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">774</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">721</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">702</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">721</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">704</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer</td><td colspan="1" rowspan="1">Sample Number</td><td colspan="1" rowspan="1">GC/MS Result</td><td colspan="1" rowspan="1">Strip FormatViewerResults</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">779</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">Negative</td></tr></table>

Discordant Results of Phencyclidine Cassette   

<table><tr><td rowspan=3 colspan=1>Cassetteformat</td><td rowspan=3 colspan=1>b</td><td rowspan=3 colspan=1>Negative</td><td rowspan=2 colspan=1>LowNegativeby GC/MS</td><td rowspan=2 colspan=1>Near CutoffNegative byGC/MS</td><td rowspan=1 colspan=1>Near CutoffPositive by</td><td rowspan=3 colspan=1>HighPositive byGC/MS(greaterthan+50%)</td></tr><tr><td rowspan=1 colspan=1>GC/MS</td></tr><tr><td rowspan=1 colspan=1>(less than-50%)</td><td rowspan=1 colspan=1>(Between-50% andcut-off)</td><td rowspan=1 colspan=1>(Betweenthe cut-offand +50%)</td></tr><tr><td rowspan=2 colspan=1>Viewer A</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer B</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer C</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Viewer</td><td rowspan=1 colspan=1>Sample Number</td><td rowspan=1 colspan=1>GC/MS Result</td><td rowspan=1 colspan=1>Cassette FormatViewer Results</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>774</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>721</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>774</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>721</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>702</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>774</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>721</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>704</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>779</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>Negative</td></tr></table>

<table><tr><td colspan="1" rowspan="1">Dip Cardformat</td><td colspan="1" rowspan="1">b</td><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">LowNegativeby GC/MS(less than-50%)</td><td colspan="1" rowspan="1">Near CutoffNegative byGC/MS(Between-50% andcut-off)</td><td colspan="1" rowspan="1">Near CutoffPositive byGC/MS(Betweenthe cut-offand +50%)</td><td colspan="1" rowspan="1">HighPositive byGC/MS(greaterthan+50%</td></tr><tr><td colspan="1" rowspan="2">Viewer A</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">24</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="2">Viewer B</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">24</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="2">Viewer C</td><td colspan="1" rowspan="1">Positive</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">24</td></tr><tr><td colspan="1" rowspan="1">Negative</td><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">0</td></tr></table>

Discordant Results of Phencyclidine Dip Card   

<table><tr><td rowspan=1 colspan=1>Viewer</td><td rowspan=1 colspan=1>Sample Number</td><td rowspan=1 colspan=1>GC/MS Result</td><td rowspan=1 colspan=1>Dip Card FormatViewer Results</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>774</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>721</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer A</td><td rowspan=1 colspan=1>779</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>774</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>721</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer B</td><td rowspan=1 colspan=1>702</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>774</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>721</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>779</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>Negative</td></tr><tr><td rowspan=1 colspan=1>Viewer C</td><td rowspan=1 colspan=1>704</td><td rowspan=1 colspan=1>27</td><td rowspan=1 colspan=1>Negative</td></tr></table>

<table><tr><td rowspan=7 colspan=1>Cupformat</td><td rowspan=7 colspan=1></td><td rowspan=7 colspan=3>Negative</td><td rowspan=5 colspan=2>LowNegative</td><td rowspan=5 colspan=1>Near CutoffNegative by</td><td rowspan=3 colspan=1>Near Cutoff</td><td></td></tr><tr><td rowspan=2 colspan=3>ive</td><td></td></tr><tr><td rowspan=3 colspan=1>HighPositive by</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=3 colspan=2>Negativeby GC/MS</td><td rowspan=2 colspan=1>Positive by</td></tr><tr><td rowspan=1 colspan=1></td></tr><tr><td rowspan=2 colspan=1>GC/MS(Between-50% andcut-off)</td><td rowspan=1 colspan=1>GC/MS</td><td rowspan=1 colspan=1>GC/MS</td></tr><tr><td rowspan=1 colspan=2>(less than-50%)</td><td rowspan=1 colspan=1>(Betweenthe cut-offand +50%)</td><td rowspan=1 colspan=1>(greaterthan+50%)</td></tr><tr><td rowspan=2 colspan=1>Viewer A</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=3>0</td><td rowspan=1 colspan=2>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=3>10</td><td rowspan=1 colspan=2>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer B</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=3>0</td><td rowspan=1 colspan=2>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=3>10</td><td rowspan=1 colspan=2>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=2 colspan=1>Viewer C</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=3>0</td><td rowspan=1 colspan=2>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=3>10</td><td rowspan=1 colspan=2>15</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr></table>

Discordant Results of Phencyclidine Cup   

<table><tr><td colspan="1" rowspan="1">Viewer</td><td colspan="1" rowspan="1">Sample Number</td><td colspan="1" rowspan="1">GC/MS Result</td><td colspan="1" rowspan="1">Cup FormatViewer Results</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">774</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">721</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer A</td><td colspan="1" rowspan="1">779</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">774</td><td colspan="1" rowspan="1">26</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">721</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer B</td><td colspan="1" rowspan="1">702</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">721</td><td colspan="1" rowspan="1">25</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">779</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">Negative</td></tr><tr><td colspan="1" rowspan="1">Viewer C</td><td colspan="1" rowspan="1">704</td><td colspan="1" rowspan="1">27</td><td colspan="1" rowspan="1">Negative</td></tr></table>

Lay-user study

A lay user study was performed at three intended user sites with 557 lay persons testing the MDMA(Ecstasy) devices and another set of 555 persons testing the Phencyclidine devices. Total of 1112 individuals performed the study. A total of 230 females and 327 males tested the MDMA(Ecstasy) samples, and 226 females and 329 males tested the Phencyclidine samples. They had diverse educational and professional backgrounds and ranged in age from 21 to $> 5 0$ years. Urine samples were prepared at the following concentrations; negative, $+ / - 7 5 \%$ , $+ / - 5 0 \%$ , $+ / - 2 5 \%$ of the cutoff by spiking drugs into drug free-pooled urine specimens. The concentrations of the samples were confirmed by GC/MS. Each sample was aliquoted into individual containers and blind-labeled. Each participant was provided with the package insert, 1 blind labeled sample and a device. The results are summarized below.

Comparison between GC/MS and Lay Person Results (MDMA(Ecstasy) Strip)   

<table><tr><td rowspan=2 colspan=1>% of Cutoff</td><td rowspan=2 colspan=1>Numberofsamples</td><td rowspan=2 colspan=1>MDMA Concentration byGC/MS(ng/mL)</td><td rowspan=1 colspan=2>Lay person results</td><td rowspan=2 colspan=1>Thepercentage ofcorrect results(%)</td></tr><tr><td rowspan=1 colspan=1>No. ofPositive</td><td rowspan=1 colspan=1>No. ofNegative</td></tr><tr><td rowspan=1 colspan=1>-100%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-75%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-50% Cutoff</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-25%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>95%</td></tr><tr><td rowspan=1 colspan=1>+25%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>625</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>95%</td></tr><tr><td rowspan=1 colspan=1>+50%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>750</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>+75% Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>875</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr></table>

Comparison between GC/MS and Lay Person Results (MDMA(Ecstasy) Cassette)   

<table><tr><td rowspan=2 colspan=1>% of Cutoff</td><td rowspan=2 colspan=1>Numberofsamples</td><td rowspan=2 colspan=1>MDMA Concentration byGC/MS(ng/mL)</td><td rowspan=1 colspan=2>Lay person results</td><td rowspan=2 colspan=1>Thepercentage ofcorrect results(%)</td></tr><tr><td rowspan=1 colspan=1>No. ofPositive</td><td rowspan=1 colspan=1>No. ofNegative</td></tr><tr><td rowspan=1 colspan=1>-100%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-75%Cutoff</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-50% Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-25% Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>95%</td></tr><tr><td rowspan=1 colspan=1>+25%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>625</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>95%</td></tr></table>

Comparison between GC/MS and Lay Person Results (MDMA(Ecstasy) DipCard)   

<table><tr><td rowspan=1 colspan=1>+50% Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>750</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>+75% Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>875</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr></table>

<table><tr><td rowspan=2 colspan=1>% of Cutoff</td><td rowspan=2 colspan=1>Numberofsamples</td><td rowspan=2 colspan=1>MDMA Concentration byGC/MS(ng/mL)</td><td rowspan=1 colspan=2>Lay person results</td><td rowspan=2 colspan=1>Thepercentage ofcorrect results(%)</td></tr><tr><td rowspan=1 colspan=1>No. ofPositive</td><td rowspan=1 colspan=1>No. ofNegative</td></tr><tr><td rowspan=1 colspan=1>-100%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-75%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-50% Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-25%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>95%</td></tr><tr><td rowspan=1 colspan=1>+25%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>625</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>95%</td></tr><tr><td rowspan=1 colspan=1>+50%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>750</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>+75%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>875</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr></table>

Comparison between GC/MS and Lay Person Results (MDMA(Ecstasy) Cup)   

<table><tr><td rowspan=2 colspan=1>% of Cutoff</td><td rowspan=2 colspan=1>Numberofsamples</td><td rowspan=2 colspan=1>MDMA Concentration byGC/MS(ng/mL)</td><td rowspan=1 colspan=2>Lay person results</td><td rowspan=2 colspan=1>Thepercentage ofcorrect results(%)</td></tr><tr><td rowspan=1 colspan=1>No. ofPositive</td><td rowspan=1 colspan=1>No. ofNegative</td></tr><tr><td rowspan=1 colspan=1>-100%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-75%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-50% Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-25%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>95%</td></tr><tr><td rowspan=1 colspan=1>+25%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>625</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>95%</td></tr><tr><td rowspan=1 colspan=1>+50%Cutoff</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>750</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>+75%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>875</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr></table>

Comparison between GC/MS and Lay Person Results (Phencyclidine Strip)   

<table><tr><td rowspan=2 colspan=1>% of Cutoff</td><td rowspan=2 colspan=1>Numberofsamples</td><td rowspan=2 colspan=1>PhencyclidineConcentration by GC/MS(ng/mL)</td><td rowspan=1 colspan=2>Lay person results</td><td rowspan=2 colspan=1>Thepercentage ofcorrect results(%)</td></tr><tr><td rowspan=1 colspan=1>No. ofPositive</td><td rowspan=1 colspan=1>No. ofNegative</td></tr><tr><td rowspan=1 colspan=1>-100%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-75%Cutoff</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-50% Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-25%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>95%</td></tr><tr><td rowspan=1 colspan=1>+25%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>95%</td></tr><tr><td rowspan=1 colspan=1>+50%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>37.5</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>+75%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr></table>

Comparison between GC/MS and Lay Person Results (Phencyclidine Cassette)   

<table><tr><td rowspan=2 colspan=1>% of Cutoff</td><td rowspan=2 colspan=1>Numberofsamples</td><td rowspan=2 colspan=1>PhencyclidineConcentration by GC/MS(ng/mL)</td><td rowspan=1 colspan=2>Lay person results</td><td rowspan=2 colspan=1>Thepercentage ofcorrect results(%)</td></tr><tr><td rowspan=1 colspan=1>No. ofPositive</td><td rowspan=1 colspan=1>No. ofNegative</td></tr><tr><td rowspan=1 colspan=1>-100%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-75%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-50% Cutoff</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-25%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>95%</td></tr><tr><td rowspan=1 colspan=1>+25%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>95%</td></tr><tr><td rowspan=1 colspan=1>+50%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>37.5</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>+75%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr></table>

Comparison between GC/MS and Lay Person Results (Phencyclidine DipCard)   

<table><tr><td rowspan=2 colspan=1>% of Cutoff</td><td rowspan=2 colspan=1>Numberofsamples</td><td rowspan=2 colspan=1>PhencyclidineConcentration by GC/MS(ng/mL)</td><td rowspan=1 colspan=2>Lay person results</td><td rowspan=2 colspan=1>Thepercentage ofcorrect results(%)</td></tr><tr><td rowspan=1 colspan=1>No. ofPositive</td><td rowspan=1 colspan=1>No. ofNegative</td></tr><tr><td rowspan=1 colspan=1>-100%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-75%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-50% Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-25%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>90%</td></tr><tr><td rowspan=1 colspan=1>+25%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>90%</td></tr><tr><td rowspan=1 colspan=1>+50%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>37.5</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>+75%Cutoff</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr></table>

Comparison between GC/MS and Lay Person Results (Phencyclidine Cup)   

<table><tr><td rowspan=2 colspan=1>% of Cutoff</td><td rowspan=2 colspan=1>Numberofsamples</td><td rowspan=2 colspan=1>PhencyclidineConcentration by GC/MS(ng/mL)</td><td rowspan=1 colspan=2>Lay person results</td><td rowspan=2 colspan=1>Thepercentage ofcorrect results(%)</td></tr><tr><td rowspan=1 colspan=1>No. ofPositive</td><td rowspan=1 colspan=1>No. ofNegative</td></tr><tr><td rowspan=1 colspan=1>-100%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-75%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-50% Cutoff</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>-25%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>90%</td></tr><tr><td rowspan=1 colspan=1>+25%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>31</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>95%</td></tr><tr><td rowspan=1 colspan=1>+50%Cutoff</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>37.5</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>+75%Cutoff</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>44</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>100%</td></tr></table>

Lay-users were also given surveys on the ease of understanding the package insert instructions. All lay users indicated that the device instructions can be easily followed. A Flesch-Kincaid reading analysis was performed on each package insert and the scores revealed a reading Grade Level of 7.

3. Clinical Studies

Not applicable.

# 11.Conclusion

Based on the test principle and acceptable performance characteristics including precision, cut-off, interference, specificity and method comparison of the devices, it’s concluded that the Healgen MDMA(Ecstasy) Test, and Healgen Phencyclidine Test are substantially equivalent to the predicate.